Axa
PGNX

Axa’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Axa’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-36,400
Closed -$225K – 1379
2019
Q2 		$225K Hold
36,400
– – ﹤0.01% 1215
2019
Q1 		$169K Sell
36,400
-37,600
-51% -$170K ﹤0.01% 1273
2018
Q4 		$311K Buy
+74,000
New +$377K ﹤0.01% 1164
2016
Q3 		– Sell
-31,900
Closed -$135K – 1400
2016
Q2 		$135K Buy
31,900
+14,800
+87% +$71.5K ﹤0.01% 1213
2016
Q1 		$75K Buy
+17,100
New +$76.2K ﹤0.01% 1229
2015
Q1 		– Sell
-23,300
Closed -$176K – 1511
2014
Q4 		$176K Buy
+23,300
New +$139K ﹤0.01% 1277
2013
Q3 		– Sell
-45,436
Closed -$203K – 1356
2013
Q2 		$203K Buy
+45,436
New +$204K ﹤0.01% 1099

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Axa's PGNX Position: Q3 2019 in Review

Axa sold out of Progenics Pharmaceuticals Inc (PGNX) in Q3 2019, closing a stake of 36,400 shares — an estimated $225K sold.

Axa first reported a position in PGNX in Q2 2013 and held it in 7 quarters. The position peaked at $311K in Q4 2018. 135 funds tracked by Wall St. Rank hold PGNX as of Q3 2019.

  • Axa reported no remaining Progenics Pharmaceuticals Inc position as of Q3 2019 after selling out during the quarter.
  • Axa sold 36,400 Progenics Pharmaceuticals Inc shares in Q3 2019, an estimated $225K.
  • Axa first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and held it in 7 quarters.
  • Axa's Progenics Pharmaceuticals Inc position peaked at $311K in Q4 2018.
  • 135 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q3 2019.

Based on Axa's 13F filing for Q3 2019, filed 14 Nov 2019.